CorWave LVAD: A Novel Pulsatile Left Ventricular Assist Device Demonstrates No Need for Long-Term Anticoagulation in Preclinical Studies

Apr 25, 2025 17:30 CST Updated 17:30

CorWave

Cardiac Assist Device Developer

CorWavePublish itsLeft Ventricular Assist Device--CorWave LVADThe in vivo study data confirmedCorWave LVADImplanted in the bodyNo long-term anticoagulation required.

This study is an animal experiment, involving 9 animalsSheep ImplantCorWave LVAD, and continuously operate for 6 months as well as during the research period60 Days of Anticoagulation-Free Treatment. DiscoveryNo device malfunction occurred during the study period, and no thrombus was observed upon removal.。

PI Evaluation

"This technology is expected to reshape the field of long-term mechanical circulatory support, overcome the limitations of existing rotary blood pumps, and achieve truly intelligent and adaptive circulatory support. Preclinical results are outstanding, with additional six-month animal experiment follow-ups showing excellent pump performance. Looking forward to its clinical application."

---Martin Strueber Cardiac Surgeon

"CorWave Adaptive Intelligent LVAD Demonstrates Excellent Preclinical Results, With No Device-Related Failures or Complications. Smooth Surgical Implantation, New Control Algorithm Enables Synchronous Support (Systolic/Diastolic Mode), Reliable Operation Throughout, Safety and Feasibility Verified."

---Sebastian Schulte Eistrup, Cardiothoracic Surgeon

Executive Evaluation

"These achievements not only meet the highest standards in the LVAD industry but also demonstrate potential clinical advantages over the rotary blood pumps that have been used since the 1990s. The team is actively promoting the clinical application of this device."

---Louis de Lillers CorWave CEO

The Relationship Between Left Ventricular Assist Devices and Anticoagulation Therapy is a Key Clinical Concern

AndCorWave LVADAnimal trials offer a new option for heart failure patients, ifCorWave LVADIn subsequent clinical studies, it has also been confirmed that patients can achieve long-term freedom from taking anticoagulants, which not only reduces the burden on patientsThe risk of bleeding, and it also allows patients to live more naturally without having to constantly think about taking anticoagulants to stay alive.

CorWave LVAD

CorWave LVADCan provide an average flow rate of 5 to 6 L/min, thereby offering comprehensive support for patients with end-stage heart failure.CorWave LVADAddressing traditional LVAD indications: "Bridge to Transplant" (BTT) for patients awaiting transplantation; "Destination Therapy" (DT) for patients unsuitable for transplantation, and "Bridge to Recovery" (BTR).

After the pump is implanted, the driveline will provide power through the skin and connect the pump to an external controller and battery.

It has the ability to reproduce physiological pulsatile blood flow, aiming to reduce existing complications and improve patients' lives.

CorWave LVADAndThird-Generation Non-Contact Centrifugal PumpTwo Major Differences

Physiological Flow Rate

Blood flows on the membrane at a physiological speed, approaching 1-2 m/s.The membrane exerts limited shear stress on blood cells, thereby maintaining the integrity of the blood, which is different from rotary pumps where blood flows at speeds exceeding 5m/s.

Pulsatile Flow Simulation

AndThird-Generation Non-Contact Centrifugal PumpDifferent,CorWave LVAProvides pulsatile flow, frequency follows heart rate, approximately 60 times per minute.

Wave Membrane Technology

Unlike the previous method of using high-speed rotating turbines to propel blood,CorWave LVADAdopted "wave membrane"Technology, which uses a high molecular membrane vibrating up and down to propel blood flow.

“wave membrane”It is a bionic technology inspired by the undulatory motion of marine animals. This movement provides an efficient way for the animals to move fluids and propel themselves through water. InCorWave LVADIn the case of polymer membranes, a similar but opposite relationship occurs: the membrane is fixed, and the liquid (blood) is propelled.

The movement of the wave can generate different membrane geometries, specifically disc-shaped and rectangular.CorWave LVADAdoptedDiscoidA membrane driven by an electromagnetic actuator, which vibrates the polymer membrane and converts the propagation of waves along the membrane (like a speaker) into the propulsion of blood.

Due to“wave membrane”Technology,CorWave LVADNot only can it maintain a pulsation like the human body, but it can also restore blood flow, which is different from the limited artificial pulsation provided by traditional LVADs.CorWave LVADIts operation is similar to that of a natural heart: it can faithfully reproduce the ejection (systolic) and filling (diastolic) phases without causing the same damage to blood as currently marketed rotary pumps in LVADs.

Wave Membrane Technology Advantages

It causes less harm to blood cells in the blood.
It can generate pulsatile blood flow similar to normal physiological conditions;
The size, weight, and complexity of LVADs manufactured using this technology have been reduced.

These advantages will help reduce complications caused by LVAD.

CorWave LVAD Working Principle

CorWave

CorWaveIs a medical technology company that develops innovative mechanical circulatory support devices.CorWaveA developed cardiac pulsation technology can mimic the flow patterns of the human heart and overcome the limitations of rotary pulsation in left ventricular assist devices (LVADs).